Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease

Pharmacopsychiatry
H YoonD K Kim

Abstract

The response to acetylcholinesterase inhibitors (AChEIs) of Alzheimer's disease (AD) patients varies depending on the genetic characteristics of the patient. We have examined the association of response to AChEIs and genetic polymorphisms in AD patients. 158 patients with AD underwent treatment with AChEIs, and the therapeutic effect was assessed with the Korean version of the Mini Mental State Examination (K-MMSE). The association of 25 SNPs located in 3 genes (CHAT, CHT and ACHE) with changes in the K-MMSE score was analyzed. The response to AChEIs in AD patients was significantly associated with 2 SNPs on the intronic region of CHAT rs2177370 (uncorrected P=0.0025, FDR controlled P=0.026) and rs3793790 (uncorrected P=0.0024, FDR controlled P=0.026). The results of our study confirmed again that genetic polymorphism of CHAT has an influence on drug response in AD.

Citations

Jun 14, 2016·Pharmacogenomics·Ramón CacabelosJuan Carlos Carril
Jan 17, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Xiuling YangTang Li
Jun 9, 2017·Pharmacogenomics·Hazel Xiaohui AngMichael D Winther
Jan 6, 2018·Journal of Personalized Medicine·Ramón CacabelosÓscar Teijido
May 3, 2020·International Journal of Molecular Sciences·Ramon Cacabelos
Jun 11, 2020·Expert Opinion on Drug Metabolism & Toxicology·Ramón Cacabelos
Feb 25, 2020·Current Alzheimer Research·Marta KowalskaJolanta Dorszewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

© 2022 Meta ULC. All rights reserved